Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst
Ginkgo Bioworks has become a penny stock -- and that's the least of its problems,
Stay updated with breaking news from Mark Massaro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ginkgo Bioworks has become a penny stock -- and that's the least of its problems,
Earnings call: Teknova sees modest revenue growth in Q1 2024
NeoGenomics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.03.
Nearly three months into 2024, it’s clear that the bullish trends are here to stay. Markets hit a bottom in late October, but since then the S&P 500 has gained 27% and now stands at more than 5,200. The NASDAQ index is up 30% from its own October 27 low point. These are bull-market numbers, and show little sign of stopping. Watching the market from Oppenheimer, chief investment strategist John Stoltzfus comments on the market outlook: “S&P 500 earnings results over the most recent two quarterly
Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2023 Earnings Call Transcript March 12, 2024 Alpha Teknova, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and thank you for standing by. Welcome to Teknova Fourth Quarter 2023 Financial Results Conference Call. […]